





Edgar Filing: ELAN CORP PLC - Form 6-K

ELAN CORPORATION, plc

By: /s/ William F. Daniel

-----  
William F. Daniel  
Company Secretary

Date: April 11, 2005

Exhibit 99.1

FOR IMMEDIATE RELEASE

Investors:  
Emer Reynolds  
Ph: 353-1-709-4000  
800-252-3526

Media:  
Anita Kawatra  
Ph: 212-407-5740  
Elizabeth Headon  
Ph: 353-1-498-0300

ELAN SETS DATE OF APRIL 28 FOR FIRST QUARTER 2005 FINANCIAL RESULTS,  
AND MAY 26 FOR THE ANNUAL GENERAL  
MEETING

Elan Announces Filing of 2004 Form 20-F with SEC

DUBLIN, IRELAND, APRIL 11, 2005--Elan Corporation, plc today announced that it will report its first quarter 2005 financial results on April 28, 2005, before U.S. and European financial markets open. The results announcement will be followed by a conference call at 8:30 a.m. Eastern Time (ET), 1:30 p.m. British Summer Time (BST) with the investment community to discuss Elan's first quarter 2005 financial results. Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to investors, members of the news media and the general public. This event will be webcast live and can be accessed by going to the Investor Relations section on Elan's website at [www.elan.com](http://www.elan.com).

Elan will hold its Annual General Meeting at 10:00 a.m. BST on May 26, 2005 at the Westin Hotel, Westmoreland Street, Dublin 2, Ireland. This event will also be webcast live and can be accessed by going to the Investor Relations section on Elan's website at [www.elan.com](http://www.elan.com).

Elan has filed with the Securities and Exchange Commission its Form 20-F for the fiscal year ended December 31, 2004 and has published its Annual Report for the fiscal year ended December 31, 2004. Both these documents are available on the Investor Relations section of Elan's website at [www.elan.com](http://www.elan.com).

About Elan

## Edgar Filing: ELAN CORP PLC - Form 6-K

Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan (NYSE: ELN) shares trade on the New York, London and Dublin Stock Exchanges.